COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,584 Articles (22,905 medRxiv, 8,679 bioRxiv)

Most recent first Previous |  Page 814: Articles 8131-8140  | Next

Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial
Shah, M. R., Fatima, S., Khan, S. N., Ullah, S., Himani, G., Wan, K. H., Lin, T. P. H., Lau, J. Y., Liu, Q., Lam, D. S. C.
10.1101/2022.05.16.22275074 — Posted: 2022-05-17
Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India
Misra, P., Kant, S., Guleria, R., Rai, S., Jaiswal, A., Mandal, S., Medigeshi, G. R., Ahmad, M., Rahman, A., Sangral, M., Yadav, K., Bairwa, M., Haldar, P., Kumar, P.
10.1101/2022.05.17.22275193 — Posted: 2022-05-17
Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination.
Kenny, G., Negi, R., O'Reilly, S., Garcia Leon, A. A., Alalwan, D., Gaillard, C. M., Saini, G., Inzitari, R., Feeney, E., Cotter, A. G., de Barra, E., Sadlier, C., Crispie, F., Gautier, V., Mallon, P., All Ireland Infectious Diseases Cohort Study
10.1101/2022.05.16.22275163 — Posted: 2022-05-17
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., Takeda, Y., Tsuge, Y., Uehara, T.
10.1101/2022.05.17.22275027 — Posted: 2022-05-17
WHAT ARE EFFECTIVE STRATEGY TO CONSTRAIN COVID-19 PANDEMIC CRISIS? LESSONS LEARNED FROM A COMPARATIVE POLICY ANALYSIS BETWEEN ITALIAN REGIONS TO COPE WITH NEXT PANDEMIC IMPACT
Coccia, M., Benati, I.
10.1101/2022.05.15.22275107 — Posted: 2022-05-17
The ATLAS™ screening assay reveals distinct CD4+ and CD8+ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity
Foti, J. J., Lema, K., Strickland, J., Tjon, E., Li, A., Rivera, A., Cabral, C., Cormier, L., Dowal, L., Rao, S., Vemulapalli, V., Flechtner, J. B.
10.1101/2022.05.17.491668 — Posted: 2022-05-17
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave
Al Jurdi, A., Morena, L., Cote, M., Bethea, E., Azzi, J., Riella, L. V.
10.1101/2022.05.17.22274980 — Posted: 2022-05-17
Unsupervised outlier detection applied to SARS-CoV-2 nucleotide sequences can identify sequences of common variants and other variants of interest
Hahn, G., Lee, S., Prokopenko, D., Abraham, J., Novak, T., Hecker, J., Cho, M., Khurana, S., Baden, L. R., Randolph, A. G., Weiss, S. T., Lange, C.
10.1101/2022.05.16.492178 — Posted: 2022-05-17
Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Qu, P., Evans, J. P., Faraone, J. N., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Mohler, P. J., Gumina, R. J., Liu, S.-L.
10.1101/2022.05.16.492158 — Posted: 2022-05-17
Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.
Rizvi, Z. A., Babele, P., Sadhu, S., Madan, U., Tripathy, M. R., Goswami, S., Mani, S., Kumar, S., Awasthi, A., Dikshit, M.
10.1101/2022.05.16.492112 — Posted: 2022-05-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).